Effects of dapagliflozin on cardiac and renal function in elderly patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction
Objective To explore the effects of dapagliflozin on cardiac and renal function in elderly patients with type 2 diabetes mellitus(T2DM)and heart failure with preserved ejection fraction(HF-PEF).Methods A total of 200 elderly patients with T2DM and HF-PEF were enrolled as the research objects.According to random number table method,they were divided into observation group(n=100)and control group(n=100).The control group was given routine treatment,while the observation group was additionally treated with dapagliflozin.The blood glucose level,cardiac function,renal function and inflammatory factors were compared between the 2 groups before and after treatment.The occurrence of adverse reactions in both groups was recorded.Results After treatment,the levels of fasting blood glucose(FBG),2 hours postprandial blood glucose(2 hPG)and glycosylated hemoglobin(HbAlc)were decreased in both groups(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)and 6 minutes walking distance were increased in both groups,which in observation group were(46.35%±7.02%)and(364.91±23.65)m,higher than those in control group[(42.18%±7.43%),(315.47±26.52)m,P<0.05].After treatment,the left ventricular end-diastolic diameter(LVEDD)and the ratio of early diastolic transmitral velocity to early diastolic mitral annular velocity(E/e')were decreased in both groups,which in observation group were(50.36±6.05)mm and(8.25±1.03),lower than those in control group[(54.01±6.84)mm,(10.15±1.24),P<0.05].After treatment,the levels of serum creatinine(Cr),uric acid(UA),cystatin C(Cys-C),C-reactive protein(CRP),interleukin-6(IL-6)and interleukin-1β(IL-1β)in observation group were(46.58±6.14)μmol·L-1,(241.52±41.05)μmol·L-1,(0.68±0.11)mg·L-1,(1.71±0.48)mg·L-1,(10.22±1.05)ng·L-1 and(32.48±4.62)ng·L-1,lower than those in control group[(67.25±6.38)μmol·L-1,(305.71±53.42)μmol·L-1,(0.76±0.15)mg·L-1,(2.13±0.57)mg·L-1,(18.43±1.26)ng·L-1,(49.51±5.17)ng·L-1,P<0.05].The difference in the incidence of adverse reactions between the 2 groups was not statistically significant(4.00%vs.6.00%,P>0.05).Conclusion Dapagliflozin can improve cardiac and renal function in elderly patients with T2DM and HF-PEF,which is beneficial to control blood glucose and reduce the levels of inflammatory factors,with certain safety.
type 2 diabetes mellitusdapagliflozinheart failure with preserved ejection fractioncardiac functionrenal function
NETL
NSTL
万方数据
维普
